Increased efficiency and quality for hemato-oncology labs
As a user, you have full control over the extent of decision support you employ: for each case, the exact confidence hema.to has in its diagnostic recommendation is made transparent.
Whether it's gating or drawing one's conclusion: high-quality diagnoses take time. hema.to recommends diagnoses in seconds, reducing time to diagnosis to increase your throughput.
Writing medical reports can be tedious. hema.to can explain the clinical reasoning behind a diagnosis, so that you can configure, adapt and export medical reports in seconds.
Medical software requires development processes that meet the highest standards. hema.to will be a CE-IVD by June 2022 and is scientifically backed by peer-reviewed publications.
We are working hard to be compliant with the In Vitro Diagnostic Directive (IVDD), meaning that we conform to ISO 13485 (quality management), ISO 14971 (risk management), ISO 62366 (usability), ISO 62304 (software life-cycle management) and IEC 82304 (health software).
We have demonstrated expert-level performance at making differential diagnoses between the most common B-NHL types and healthy patients. Our mean accuracy was > 99% in a trial with >4k cases. Human intervention would have been unnecessary in more than 75% of cases (trial publication).
Our application performs client-side anonymization, which means that your patient's name never even reaches our servers.
The world's largest laboratory networks trust hema.to to improve their workflows
“Nobody integrates as much data as hema.to.“
“In the long run, there will be only three specialized hematology labs in the Netherlands — I think that hema.to will help us to be amongst them.“
“hema.to's quantitative diagnosis is revolutionary.“
We will not share your data with any third parties.